Sociedad Americana de Hirudoterapia

MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis

Review published in Nature reviews. Drug discovery (2006)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosMorand EF et al. · Nature reviews. Drug discovery, 2006

Abstract

Macrophage migration inhibitory factor (MIF) is well established as a key cytokine in immuno-inflammatory diseases such as rheumatoid arthritis. Inflammation is now also recognized as having a crucial role in atherosclerosis, and recent evidence indicates that MIF could also be important in this disease. Here, we review the role of MIF in rheumatoid arthritis and atherosclerosis, discuss the ways in which MIF and its relationship with glucocorticoids could link these diseases, and consider the potential of MIF as a new therapeutic target for small-molecule and antibody-based anti-cytokine drugs.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tReview
Indexed MeSH termsAnimalsArthritis, RheumatoidAtherosclerosisGlucocorticoidsHumansMacrophage Migration-Inhibitory Factors

Resumen

Macrophage migration inhibitory factor (MIF) is well established as a key cytokine in immuno-inflammatory diseases such as rheumatoid arthritis.

Por qué esto importa para la hirudoterapia

This review examines macrophage migration inhibitory factor (MIF) as a cytokine linking rheumatoid arthritis and atherosclerosis, discussing its role in both diseases, its relationship with glucocorticoids, and its potential as a therapeutic target for small-molecule and antibody-based anti-cytokine drugs. While inflammation in rheumatoid arthritis is sometimes cited in complementary medicine literature related to leech therapy, this abstract contains no mention of leeches, hirudotherapy, leech-derived compounds, or any related substance. There is no defensible connection to the leech secretome or ASH's research domain based on this abstract.

Citación

MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis

Morand EF et al. · Nature reviews. Drug discovery, 2006

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsAnti-Inflammatory MechanismsAnti-Inflammatory CompoundsAtherosclerosis MechanismsCardiovascularMusculoskeletalPain Syndromes

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.